Form 4: Revolution Medicines Director Lorence H. Kim Reports Significant Equity Grant

Revolution Medicines, Inc. Director Lorence H. Kim reported the acquisition of 3,142 shares of common stock and 11,574 stock options as part of an equity grant.

Summary

• Lorence H. Kim, a Director of Revolution Medicines, Inc. (RVMD), reported changes in beneficial ownership.
• Acquired 3,142 shares of common stock at a price of $0.
• Acquired 11,574 stock options with an exercise price of $37.48.
• Following these transactions, Lorence H. Kim beneficially owns 73,090 shares of common stock, which includes 4,017 Restricted Stock Units (RSUs).
• The 11,574 stock options have an expiration date of June 26, 2035.
• The stock options vest in full on the earlier of June 26, 2026 (first anniversary of grant) or immediately prior to the Annual Meeting following the grant date, contingent on remaining a Service Provider.

Sentiment

Score: 6

Explanation: The filing indicates a routine equity grant to a director, which is generally viewed positively as it aligns management's interests with shareholders, but it does not contain significant new operational or financial information to drive strong sentiment.

Positives

• The grant of common stock and stock options to Director Lorence H. Kim aligns his interests with those of shareholders, incentivizing long-term performance.

Negatives

• No explicit negative information is contained in this Form 4 filing, which primarily reports insider transactions.

Risks

• This Form 4 filing does not contain information regarding company-specific risks.

Future Outlook

The stock options granted are subject to future vesting conditions, specifically full vesting on the earlier of the first anniversary of the grant date (June 26, 2026) or immediately prior to the Annual Meeting following the grant date, provided the reporting person remains a Service Provider.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

The grant of equity, including common stock and stock options, to a director is a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key leadership by aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• This Form 4 filing details an individual insider transaction and does not provide sufficient information for a direct comparison to specific industry benchmarks or comparable companies' executive compensation structures.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are reported in this Form 4 filing.

Related Party Transactions

• The reported equity grant to a director constitutes a related party transaction, which is a standard component of executive compensation.

Stakeholder Impact

• Shareholders: The equity grant to a director aligns their long-term interests with shareholder value creation.
• Employees: While specific to a director, this type of equity compensation reflects a broader strategy of incentivizing key personnel, which can positively influence employee retention and motivation.

Next Steps

• The stock options are subject to future vesting, with full vesting occurring on the earlier of June 26, 2026, or immediately prior to the Annual Meeting following the grant date, contingent on the director remaining a Service Provider.

Key Dates

Keywords

Revolution Medicines, RVMD, Lorence H. Kim, Director, SEC Form 4, insider transaction, stock options, common stock, equity grant, beneficial ownership